A phase II clinical trial (NCT02130466) in BRAF-mutant melanoma showed that the triplet combination of dabrafenib, trametinib, and pembrolizumab had a longer median PFS (Progression-free Survival) (16.0 vs. 12.5 months, respectively; p = 0.043) and a higher response rate (59.8% vs. 27.8%, respectively) with a higher rate of grade 3/4 adverse events (58.3% vs. 26.7%, respectively) than the doublet combination of dabrafenib and trametinib [123]. This evidence concerns the gene BRAF and melanoma.